Logo image of SXTC

CHINA SXT PHARMACEUTICALS IN (SXTC) Stock Analyst Earnings Estimates

NASDAQ:SXTC - Nasdaq - VGG2161P1577 - Common Stock - Currency: USD

1.58  -0.03 (-1.86%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2022 2023 2024
Revenue
YoY % growth
SXTC revenue by date.SXTC revenue by date.
2.6M
-45.61%
1.97M
-24.23%
1.929M
-2.11%
EBITDA
YoY % growth
SXTC ebitda by date.SXTC ebitda by date.
-4.87M
-163.24%
-5.01M
-2.87%
-1.889M
62.29%
EBIT
YoY % growth
SXTC ebit by date.SXTC ebit by date.
-5.19M
-135.91%
-5.26M
-1.35%
-2.092M
60.22%
Operating Margin
SXTC operating margin by date.SXTC operating margin by date.
-199.62%-267.01%-108.49%
EPS
YoY % growth
SXTC eps by date.SXTC eps by date.
N/AN/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2025
Q2Q % growth
829.5K
-11.72%
%
Q4 2024
Q2Q % growth
988.9K
30.12%
%
Q2 2024
Q2Q % growth
939.6K
-22.35%
%
Q4 2023
Q2Q % growth
760K
-51.59%
%
Q2 2023
Q2Q % growth
1.21M
17.48%
%
Q4 2022
Q2Q % growth
1.57M
70.65%
%
Q2 2022
Q2Q % growth
1.03M
-73.32%
%
Q4 2021
Q2Q % growth
920K
-52.82%
%
Q2 2021
Q2Q % growth
3.86M
19.88%
%
Q4 2020
Q2Q % growth
1.95M
-36.89%
%
Q2 2020
Q2Q % growth
3.22M
-17.86%
%
SXTC Yearly Revenue VS EstimatesSXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A